Fractures, Compression

MEMPHIS, Tenn.--( BUSINESS WIRE )--Memphis Vascular Center (MVC), a medical practice specializing in vascular and interventional radiology, has opened a new outpatient center to serve patients throughout the Memphis area. The center’s doctors provide high quality diagnostic and minimally invasive treatment for vascular disease, cancer and other health conditions. “Interventional radiology is rapidly becoming the standard of care for treating certain health issues that once required surgery,” says MVC medical director and interventional radiologist Scott Osborne, M.D. “Thanks to our new center, patients can be treated in an outpatient setting, where convenience and exceptional care are the priority. Other benefits include a lower risk of hospital-acquired infections and lower overall cost.” The new center houses a combination of state-of-the-art diagnostic imaging equipment and treatment rooms. The treatments are performed by a team of interventional radiologists, doctors who specialize in using imaging to perform minimally invasive treatments for various conditions. “The solutions we offer are some of the most highly advanced medical procedures available today,” Dr. Osborne adds. “For example, fibroids within the uterus affect about 40% of women over 35. Each year, hundreds of thousands of women undergo hysterectomy or myomectomy to treat their fibroids. However, surgically removing fibroids from the uterus—or removing the uterus itself—is no longer required to treat this condition. With interventional radiology, we block or ‘embolize’ the blood vessels that feed the fibroid. Without a blood supply, the fibroids shrink and symptoms disappear. No open surgery required, no scarring, very little recovery time and lasting results.” Conditions treated at the new center include:: Peripheral arterial disease (PAD) and critical limb ischemia (CLI) Varicose veins Liver cancer Uterine fibroids Enlarged prostate causing urinary trouble Knee pain from osteoarthritis Chronic bleeding hemorrhoids Spinal compression fractures All procedures offered are FDA-cleared. They are virtually pain-free, and do not require general anesthesia. In most cases, patients can return home the same day as their procedure and resume normal activities shortly thereafter. About Memphis Vascular Center The doctors of Memphis Vascular Center are among the region’s most experienced specializing in the minimally invasive treatment of diseases and health conditions. Vascular and interventional radiology is a method of treating disease from inside the body, without open surgery. This results in less trauma for the patient, lower risk of complications, shorter recovery time and virtually no scarring. Additionally, these treatments are performed in our outpatient center, a safe and convenient alternative to a hospital. Our doctors are fellowship trained in vascular and interventional radiology. With more than 13 years of education, they are among the most highly trained doctors practicing medicine and are uniquely qualified to provide both diagnostic evaluations as well as the required treatment. MemphisVascular.com

Currently more than two-thirds of spinal fractures stay undiagnosed. IB Lab FLAMINGO analyzes any CT images of the upper extremities (thorax, abdomen) that include the spine. Therefore, no additional examinations, radiation exposure or costs are required. Developed by UCB, a global biopharmaceutical company, IB Lab FLAMINGO is integrated into ImageBiopsy Lab's ZOO MSK platform, targeting hospitals to reduce overlooked spinal fractures and support early diagnosis and treatment of osteoporosis. VIENNA, Nov. 29, 2023 /PRNewswire/ -- ImageBiopsy Lab, a pioneer in medical imaging, introduces IB Lab FLAMINGO at this year's RSNA conference. The fully automated software identifies asymptomatic spinal fractures in CT scans. Utilizing the gold standard Genant classification, IB Lab FLAMINGO highlights relevant fractures and empowers proactive treatment for healthcare professionals. "Our partnership with UCB highlights the potential of leveraging AI for improving care for many diseases, including osteoporosis" explains Richard Ljuhar, CEO at ImageBiopsy Lab. Understanding the Osteoporosis Challenge "Together with expert clinicians, UCB developed this deep-learning computational model that can detect vertebral compression fractures on CT scans. ImageBiopsy Lab as a musculoskeletal (MSK) radiology AI company has refined the technology and is now ready to integrate it into clinical care. Given that 80% of fragility fractures today remain undiagnosed and untreated, we're excited about the potential of IB Lab FLAMINGO to help close the global treatment gap in osteoporosis", said Jen Timoshanko, Head of Medical Affairs, Bone Health Mission at UCB. Osteoporosis impacts around 200 million globally, leading to 9 million fragility fractures annually, most of them vertebral (VFs). Its silent progression can cause pain, reduced mobility, and diminished quality of life. Apart from personal suffering, fragility fractures strain global public health systems, escalating treatment costs and mortality rates, posing societal challenges. "In an ageing society, osteoporosis and its consequences, especially geriatric fractures, challenge patients, physicians, and healthcare systems. IB Lab FLAMINGO's ability to detect vertebral fractures offers a crucial, automated solution for early risk assessment and targeted treatment in addressing osteoporosis complexities." Prof. Andreas Kurth, Director of the Center for Orthopaedics and Trauma Surgery at Marienhaus Klinikum Mainz, Germany, expressed the need for a meaningful solution. Annalisa Blaha marketing@imagebiopsy.com +43 1905 12061104 About ImageBiopsy Lab Vienna-based ImageBiopsy Lab is at the forefront of medical imaging technology, developing innovative AI solutions to improve patient outcomes. -> Follow us on LinkedIn About UCB UCB, is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. UCB is listed on Euronext Brussels (symbol: UCB). -> Follow us on Twitter: @UCB_news. Note: The information provided in this press release is accurate as of the date of publication and is subject to change without notice. Photo - Logo - View original content to download multimedia: SOURCE ImageBiopsy Lab

Pioneering Safer and More Effective Solutions for Vertebral Fractures THE HAGUE, Netherlands, Oct. 3, 2023 /PRNewswire/ -- Amber Implants, an innovative medical technology company developing next-generation implants for spinal injuries, today announces the official start of the clinical trials for the VCFix® Spinal System. This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. The study is being led by Prof. Dr. Robert Pflugmacher, at the Clinic for Orthopaedics of the Mechernich Hospital in Germany. He was very pleased with the device's performance regarding the ease of the procedures and the initial results for the patient. Dr. Banafsheh Sajadi, Co-Founder and Chief Executive Officer, Amber Implants added "This news marks a key milestone in the product development of the VCFix® Spinal System, and we aim to expand the clinical trial to further validate the device's versatile applications. Our comprehensive approach is a significant leap forward in spinal healthcare, promising safer and more effective treatments for patients with both traumatic and osteoporotic vertebral fractures." Over 8.6 million people per annum suffer from different types of vertebral fractures. These fractures cause severe back pain, limited mobility, and an increased rate of mortality, in an already vulnerable elderly population. Currently, vertebral compression fractures are managed through the injection of Polymethyl methacrylate (PMMA) bone cement into the affected vertebra or with multi-level posterior fixation. This can lead to side effects in up to two-thirds of patients, post-treatment. The VCFix® Spinal System offers an innovative strategy for managing a diverse range of vertebral fractures and is poised to eliminate the need for bone cement while ensuring continued compatibility. This system is designed to be applicable for both single- and multi-level posterior fixation and is engineered for superior mechanical strength, maximum fracture reduction, and anatomical restoration. The VCFix implant not only encourages natural healing but also enhances stability and optimizes load distribution within the spine through pedicle anchorage. About Amber Implants Amber Implants is a medical technology company located in the Netherlands and United States. Founded in 2018, the Company has developed novel spinal implants for Vertebral Compression Fractures (VCF) and is focused on improving patient outcomes through implants that provide more natural healing and better stability. Amber Implants is committed to delivering a new generation of treatments for traumatic fractures, promising a simpler, more efficient, and safer approach to treating a broader range of fractures. SOURCE Amber Implants